SR-0379(SR-0379) - 药物靶点：Akt-1 x Class I PI3K x mTOR_在研适应症：皮肤溃疡_专利_临床

概要

基本信息

药物类型

合成多肽

别名

靶点

Akt-1 x Class I PI3K x mTOR

作用机制

Akt-1抑制剂(丝氨酸/苏氨酸蛋白激酶AKT抑制剂)、Class I PI3K抑制剂(磷脂酰肌醇激酶I型复合体抑制剂)、mTOR抑制剂(丝氨酸/苏氨酸蛋白激酶mTOR抑制剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C121H222N42O21S2

InChIKeyIVQFHGVEBLGBEL-RQEVABAPSA-N

CAS号1639363-19-1

序列信息

Sequence Code 1495702

关联

6

项与 SR-0379 相关的临床试验

JPRN-jRCT2031210266 / Not yet recruiting临床3期IIT

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of SR-0379 in Participants with Skin Ulcer

开始日期2021-08-02

申办/合作机构-

JPRN-JapicCTI-183996 / Completed临床2期

A phase 2 study of SR-0379 in patients with cutaneous ulcer (pressure ulcer, diabetic ulcer)

开始日期2018-07-04

申办/合作机构

Shionogi & Co., Ltd.

JPRN-jRCT2080223939 / Completed临床2期

A phase 2 study of SR-0379 in patients with cutaneous ulcer (pressure ulcer, diabetic ulcer)

开始日期2018-07-04

申办/合作机构

Shionogi & Co., Ltd.

100 项与 SR-0379 相关的临床结果

登录后查看更多信息

100 项与 SR-0379 相关的转化医学

登录后查看更多信息

100 项与 SR-0379 相关的专利（医药）

登录后查看更多信息

4

项与 SR-0379 相关的文献（医药）

2019-11-01·Geriatrics & Gerontology International3区 · 医学

Investigator‐initiated clinical study of a functional peptide, SR‐0379, for limb ulcers of patients with Werner syndrome as a pilot study

3区 · 医学

Article

作者: Yokote, Koutaro ; Kiyohara, Eiji ; Yao, Xiang Jing ; Takemoto, Minoru ; Nakagami, Hironori ; Nakamura, Ayumi ; Ishikawa, Takahiro ; Rakugi, Hiromi ; Ebihara, Tamotsu ; Takami, Yoichi ; Nishikawa, Mitsunori ; Hayashi, Misa ; Yamamoto, Koichi ; Nakagawa, Yukinobu ; Hanaoka, Hideki ; Sugimoto, Ken ; Fujimoto, Taku ; Koshizaka, Masaya ; Takeya, Yasushi ; Terabe, Yuta ; Ando, Hiroshi

AimAn investigator‐initiated clinical study was carried out to evaluate the therapeutic potency of SR‐0379 for the treatment of leg ulcers in patients with Werner syndrome.MethodsA multicenter, open‐label study was carried out from September 2017 to February 2018. The inclusion criteria for leg ulcers were: (i) leg ulcers in patients with Werner syndrome, diabetes or critical limb ischemia/venous stasis; and (ii) a wound size of >1 cm and <6 cm in diameter. Four individuals with Werner syndrome and diabetic ulcers, respectively, were enrolled. SR‐0379 (0.1%) was sprayed on skin ulcers once per day for 4 weeks. Efficacy was evaluated by determining the rate of wound size reduction as a primary end‐point at 4 weeks after the first treatment compared with the pretreatment wound size. As secondary end‐points, the DESIGN‐R score index, the 50% wound size reduction ratio, time to wound closure and quantification of wound bacteria were also evaluated. The safety of SR‐0379 was evaluated during the study period.ResultsThe reduction rate of ulcer size treated with 0.1% SR‐0379 was 22.90% (mean) in the Werner syndrome ulcers group (n = 4) and 35.70% (mean) in the diabetic ulcers group (n = 4), respectively. The DESIGN‐R score decreased by 4.0 points in the Werner syndrome ulcers group and 4.3 points in the diabetic ulcers group. Two mild adverse events were reported in two patients, and causal relationships were denied in any events.ConclusionTreatment with SR‐0379 was safe, well‐tolerated, and effective for leg ulcers of both Werner syndrome and diabetes patients. Geriatr Gerontol Int 2019; 19: 1118–1123.

2017-10-31·BMB Reports4区 · 生物学

The anti-microbial peptide SR-0379 stimulates human endothelial progenitor cell-mediated repair of peripheral artery diseases

4区 · 生物学

ArticleOA

作者: Park, Gyu Tae ; Kim, Seung-Chul ; Heo, Soon Chul ; Kwon, Yang Woo ; Yoon, Jung Won ; Lee, Tae Wook ; Jang, Il Ho ; Kim, Jae Ho

Ischemia is a serious disease, characterized by an inadequate blood supply to an organ or part of the body. In the present study, we evaluated the effects of the anti-microbial peptide SR-0379 on the stem cell-mediated therapy of ischemic diseases. The migratory and tube-forming abilities of human endothelial progenitor cells (EPCs) were enhanced by treatment with SR-0379 in vitro. Intramuscular administration of SR-0379 into a murine ischemic hindlimb significantly enhanced blood perfusion, decreased tissue necrosis, and increased the number of blood vessels in the ischemic muscle. Moreover, co-administration of SR-0379 with EPCs stimulated blood perfusion in an ischemic hindlimb more than intramuscular injection with either SR-0379 or EPCs alone. This enhanced blood perfusion was accompanied by a significant increase in the number of CD31- and α-SMApositive blood vessels in ischemic hindlimb. These results suggest that SR-0379 is a potential drug candidate for potentiating EPC-mediated therapy of ischemic diseases. [BMB Reports 2017; 50(10): 504-509].

PLoS ONE3区 · 综合性期刊

Novel Anti-Microbial Peptide SR-0379 Accelerates Wound Healing via the PI3 Kinase/Akt/mTOR Pathway

3区 · 综合性期刊

ArticleOA

作者: Saito, Yoshimi ; Tenma, Akiko ; Kaneda, Yasufumi ; Tomono, Kazunori ; Morishita, Ryuichi ; Nakagami, Hironori ; Kanamori, Toshihide ; Tomioka, Hideki ; Tamura, Nao ; Kaga, Toshihiro

We developed a novel cationic antimicrobial peptide, AG30/5C, which demonstrates angiogenic properties similar to those of LL-37 or PR39. However, improvement of its stability and cost efficacy are required for clinical application. Therefore, we examined the metabolites of AG30/5C, which provided the further optimized compound, SR-0379. SR-0379 enhanced the proliferation of human dermal fibroblast cells (NHDFs) via the PI3 kinase-Akt-mTOR pathway through integrin-mediated interactions. Furthermore SR-0379 promoted the tube formation of human umbilical vein endothelial cells (HUVECs) in co-culture with NHDFs. This compound also displays antimicrobial activities against a number of bacteria, including drug-resistant microbes and fungi. We evaluated the effect of SR-0379 in two different would-healing models in rats, the full-thickness defects under a diabetic condition and an acutely infected wound with full-thickness defects and inoculation with Staphylococcus aureus. Treatment with SR-0379 significantly accelerated wound healing when compared to fibroblast growth factor 2 (FGF2). The beneficial effects of SR-0379 on wound healing can be explained by enhanced angiogenesis, granulation tissue formation, proliferation of endothelial cells and fibroblasts and antimicrobial activity. These results indicate that SR-0379 may have the potential for drug development in wound repair, even under especially critical colonization conditions.

100 项与 SR-0379 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
皮肤溃疡	临床3期	日本	Shionogi & Co., Ltd.	2022-01-30
皮肤溃疡	临床3期	日本	FunPep Co., Ltd.	2022-01-30
压疮	药物发现	日本	Shionogi & Co., Ltd.	2018-06-27